Literature DB >> 14979055

[Recent advances in the case management of colorectal cancer liver metastases].

Bernard Nordlinger1, Stéphane Benoist.   

Abstract

For a long time, patients with liver metastases from colorectal cancer were considered to be incurable. Over the last 30 years, the benefits of surgical resection and systemic chemotherapy have been established. To date, surgical resection remains the only treatment that can ensure long-term survival and cure in some patient. However, only a minority of patients with liver metastases are amenable to surgery and after resection of liver metastases, recurrences are still observed in two third of patients. Therefore, efforts have been made to increase the number of patients that could be candidates for surgery and to decrease the risk of recurrence after surgical resection. Shrinkage of tumours after administration of pre-operative chemotherapy and the availability of new surgical technique, including portal vein embolization, cryotherapy and radiofrequency ablation, now allows the treatment, with curative intent, of metastases initially considered as non-resectable. Chemotherapy regimens have been developed to decrease the risk of postoperative recurrence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14979055

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  2 in total

Review 1.  Multisciplinary management of patients with liver metastasis from colorectal cancer.

Authors:  Kathleen De Greef; Christian Rolfo; Antonio Russo; Thiery Chapelle; Giuseppe Bronte; Francesco Passiglia; Andreia Coelho; Konstantinos Papadimitriou; Marc Peeters
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

2.  Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?

Authors:  Thiery Chapelle; Bart Op De Beeck; Ivan Huyghe; Sven Francque; Ann Driessen; Geert Roeyen; Dirk Ysebaert; Kathleen De Greef
Journal:  HPB (Oxford)       Date:  2016-03-21       Impact factor: 3.647

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.